Shingles Vaccine and Dementia Risk Reduction

Shingles Vaccination Correlates with Lower Dementia Rates

Research indicates that individuals who receive the shingles vaccine may have a lower risk of developing dementia. Data from multiple regions suggest a consistent association between vaccination and a reduction in dementia diagnoses over several years.

Regional Study Findings

Replication studies across different countries have shown varying levels of absolute reduction in dementia diagnoses:

• United Kingdom: A study observed a marked difference in dementia rates between cohorts based on a hard age cutoff for vaccine eligibility. Those eligible for the vaccine showed significantly lower rates of dementia compared to those who were too old to qualify.
• Australia: A replication study found a 1.8% absolute reduction in dementia diagnoses over 7.4 years.
• Canada: A replication study showed a 2% absolute reduction over 5.5 years.
• Initial Study: An earlier study reported a 3.5% absolute reduction over seven years, although this result featured a wide confidence interval.

Debates on Causality and Statistical Validity

While the association is strong, there is significant debate among researchers and technical observers regarding whether the vaccine causes the reduction in dementia or if the finding is a result of "spurious" data.

The "Hospital Visit" Hypothesis

One prominent counter-argument suggests that the reduction in dementia diagnoses is a statistical illusion. The theory posits that people who are vaccinated against shingles are less likely to visit hospitals because they do not contract shingles. Consequently, they are less likely to receive an incidental diagnosis of dementia during a hospital visit, leading to an undercounting of cases in the vaccinated group.

The Adjuvant and Immune Stimulation Theory

Some hypothesize that the protection may not be specific to the shingles virus but rather a result of general immune system stimulation.

"The idea that the AS01 adjuvant is involved in the dementia protection is very much alive and an ongoing topic. A paper from last year looked into it and found that the Shingrix shingles vaccine and the RSV vaccine are about the same in their risk reduction for dementia."

This suggests that the AS01 adjuvant used in certain vaccines might be the primary driver of the protective effect rather than the vaccine's target antigen.

Clinical Considerations and Vaccine Versions

There is a critical distinction between the older live-attenuated vaccine (Zostavax) and the newer recombinant vaccine (Shingrix).

• Zostavax: Much of the early evidence regarding anti-dementia effects was linked to this older version. Some critics argue that these findings were a statistical illusion.
• Shingrix: It is currently unclear if the dementia-reducing effect is as robust or present in the newer Shingrix vaccine, as case-control studies proving causation are still lacking.

Practical Implications for Patients

Beyond the potential for dementia prevention, the shingles vaccine is primarily used to prevent the virus itself and its severe complications.

Risk of Postherpetic Neuralgia

Shingles can lead to permanent nerve damage and postherpetic neuralgia, a chronic pain condition that can be debilitating and difficult to manage. Early intervention with antivirals is recommended for those who cannot be vaccinated.

Accessibility and Cost

For those without insurance, the cost of the Shingrix vaccine is approximately $500 for the two-dose series. While public health recommendations often target age 50, the virus can infect individuals in their 30s and 40s, leading some with genetic predispositions to Alzheimer's or a history of shingles to seek the vaccine earlier out-of-pocket.